NVO

诺和诺德
NYSE

实时行情|Nasdaq Last Sale

63.85
+0.34
+0.54%
盘后: 63.85 0 0.00% 16:52 02/21 EST
开盘
63.74
昨收
63.51
最高
64.05
最低
63.52
成交量
87.35万
成交额
--
52周最高
64.82
52周最低
46.47
市值
1,501.75亿
市盈率(TTM)
25.98
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测NVO价格均价为65.72,最高价位65.72,最低价为65.72。

EPS

NVO 新闻

更多
  • A Plan to Use Blockchain to Stop Counterfeit Drugs Moves Forward
  • MotleyFool.com · 22小时前
  • Oscar Health Cuts Co-Pays on About 100 Drugs to $3
  • MotleyFool.com · 22小时前
  • NASH: The Second Wave
  • Seeking Alpha - Article · 1天前
  • Oscar Health unveils program for lower drug prices, including insulin
  • Yahoo Finance · 1天前

所属板块

制药
+0.60%
制药与医学研究
+0.54%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

NVO 简况

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
展开

微牛提供Novo Nordisk A/S (ADR)(NYSE-NVO)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的NVO股票新闻,以帮助您做出投资决策。